The 2026 ESC Guidelines for the Management of Heart Failure were officially released at the European Society of Cardiology (ESC) Congress 2026, held in Munich, Germany, on August 28, 2026. The guidelines task force co-chairs, Prof. Marianna Adamo of the University of Brescia, Italy, and Prof. Lars Køber of Copenhagen University Hospital, Denmark, provided systematic commentary on four core topics: the simplification of HF classification, the restructuring of treatment terminology, earlier diagnostic thresholds, and upgraded recommendations for decompensated and advanced HF. Multiple clinical experts also demonstrated application of the new recommendations through real-world cases, offering participants a comprehensive view from theory to practice. Heart failure management is entering a new era of precision intervention across the full disease course.
Article Key Points
- HF classification is simplified from three categories to two: HFrEF (LVEF<50%) and HFpEF (LVEF≥50%); the previously intermediate HFmrEF category is removed.
- Treatment terminology is reorganized into foundational medical therapy (FMT), additional medical therapy (AMT), and guideline-directed interventional therapy (GDIT), replacing the older GDMT concept.
- Diagnostic thresholds shift earlier, with age-stratified NT-proBNP cutoffs (<50 yr ≥125 pg/mL; 50-75 yr ≥250 pg/mL; >75 yr ≥500 pg/mL), a stricter BP target of <130 mmHg (class IA), and routine UACR testing.
- The term “acute HF” is replaced by “decompensated HF,” and new evidence (PUSH-AHF, ENACT-HF) supports urine sodium-guided or protocolized diuretic strategies in hospitalized patients.
- Advanced HF diagnostic criteria are loosened, early referral to advanced HF centers receives a class I (A) recommendation, and LVAD is upgraded from class IIa to class I (evidence level C).
From a Three-Tier to a Two-Type System: LVEF 50% as the Sole Cutoff
The most visible change in the new guidelines is the simplification of HF classification. The previous three-tier system of “heart failure with reduced ejection fraction (HFrEF, LVEF<40%),” “heart failure with mildly reduced ejection fraction (HFmrEF, LVEF 41%-49%),” and “heart failure with preserved ejection fraction (HFpEF, LVEF≥50%)” has been comprehensively restructured, and the intermediate HFmrEF category has been formally removed. The new two-type system defines HFrEF as LVEF<50% and HFpEF as LVEF≥50%.
This adjustment is more than a numerical exercise. As Prof. Adamo explained, the HFmrEF category was originally introduced because of clinical trial entry criteria, but HFmrEF shares similar underlying pathophysiology with HFrEF and responds similarly to the same treatment strategies. From a pathophysiological perspective, patients with LVEF 41%-49% also have impaired systolic function, with risk factors and etiologic features that overlap substantially with those of patients with LVEF<40%. More importantly, heart failure disease-modifying treatments previously shown to be effective in LVEF<40% populations have also demonstrated benefit in patients with LVEF 41%-49%.
The clinical practicability of the new classification was illustrated during the practical session with the case of a 42-year-old man admitted for abdominal pain. ECG showed possible left axis deviation and left ventricular hypertrophy, and further workup revealed an NT-proBNP of 185 pg/mL (normal <125 pg/mL for age <50) and echocardiography showed an LVEF of approximately 45% with mild LV dilation. Under the new guidelines, this patient is clearly classified as HFrEF (LVEF<50%) and is started on foundational medical therapy (FMT) including a beta-blocker, an angiotensin receptor-neprilysin inhibitor (ARNI), and a sodium-glucose cotransporter 2 (SGLT2) inhibitor. This case vividly illustrates the clinical practicality of the new classification.
In parallel, the A-D staging framework, which advances prevention to the stages of risk factors and structural cardiac abnormalities, is also introduced.
Table 1. A-D four-stage framework for heart failure.
|
Stage |
Name |
Core Definition |
|
Stage A |
High Risk (At Risk) |
Presence of heart failure risk factors (e.g., hypertension, diabetes, obesity, etc.) without signs or symptoms of heart failure, and no abnormalities in cardiac structure or function. |
|
Stage B |
Pre-Heart Failure (Pre-HF) |
Presence of cardiac structural or functional abnormalities (e.g., left ventricular hypertrophy, reduced LVEF, elevated natriuretic peptides) without signs or symptoms of heart failure. |
|
Stage C |
Symptomatic Heart Failure (Symptomatic HF) |
Presence of cardiac structural or functional abnormalities with current or prior signs and/or symptoms of heart failure. |
|
Stage D |
Advanced Heart Failure (Advanced HF) |
Despite optimal medical and device therapy, persistent severe heart failure symptoms, severe cardiac dysfunction, severely limited exercise capacity, and recurrent heart failure events |
Staging and classification together form the “weft and warp” of the new guidelines, with staging covering the full disease course horizontally and classification guiding precision treatment vertically.
From “GDMT” to “FMT”: A Systematic Restructuring of Treatment Terminology
If classification simplification represents subtraction, the treatment terminology overhaul represents structural reorganization. Since the introduction of the GDMT concept in 2013, heart failure drug therapy has evolved from a handful of agents to multi-drug combination regimens. As Prof. Køber noted, “If you ask 20 cardiologists what GDMT means, you will get 20 different answers,” underscoring the practical urgency of this terminology update.
The new guidelines divide treatment into three layers:
- Foundational Medical Therapy (FMT): drugs applicable to the general HF population with class I recommendations and robust evidence of reducing HF hospitalization and/or mortality. FMT for HFrEF includes beta-blockers, angiotensin-converting enzyme inhibitors (ACEi), ARNI, angiotensin II receptor blockers (ARB), mineralocorticoid receptor antagonists (MRA), and SGLT2 inhibitors; FMT for HFpEF includes MRAs and SGLT2 inhibitors.
- Additional Medical Therapy (AMT): drugs with class IIa/IIb recommendations, or class I recommendations restricted to specific subgroups or aimed primarily at improving symptoms/quality of life, such as diuretics, digoxin, vericiguat, and glucagon-like peptide-1 receptor agonists (GLP-1RA).
- Guideline-Directed Interventional Therapy (GDIT): all non-pharmacological interventions, including device therapy, comorbidity-related interventions, and treatments for advanced HF.
Prof. Køber emphasized that this nomenclature is dynamic: as new evidence emerges, drugs may be “upgraded” from AMT to FMT. GDMT remains as an umbrella term, with FMT and AMT as its subsets.
Notably, MRAs receive a class IA recommendation independent of LVEF in the 2026 guidelines. SGLT2 inhibitors likewise receive a class IA recommendation for all symptomatic HF patients regardless of LVEF. During the practical session, experts also discussed the order of FMT initiation: for newly diagnosed patients with acceptable blood pressure and mild symptoms, multiple drugs may be started simultaneously and relatively aggressively, whereas in patients with significant volume overload, diuretics should be prioritized to correct fluid retention, and once volume status is stable and serum potassium is normal, an MRA may be added to improve myocardial remodeling and reduce long-term adverse event risk.
Diagnosis and Prevention: Earlier Detection and Precise Identification
After clarifying treatment layers, the new guidelines further shift management focus upstream, emphasizing prevention. Hypertension targets are tightened: a blood pressure target of <130 mmHg receives a class IA recommendation. The use of SGLT2 inhibitors in patients with type 2 diabetes and CKD or cardiovascular disease is continued, and GLP-1RAs receive a class IIa recommendation in HFpEF patients with obesity.
At the diagnostic level, age-stratified thresholds for natriuretic peptide testing are introduced: NT-proBNP ≥125 pg/mL for age <50; ≥250 pg/mL for age 50-75; and ≥500 pg/mL for age >75. This adjustment is based on the observation that in healthy adults aged over 80, nearly 80% of individuals already have NT-proBNP levels exceeding the previous uniform threshold of 125 pg/mL. Raising the diagnostic cutoff in older populations therefore helps reduce unnecessary referrals while improving diagnostic specificity. Laboratory testing also newly includes urine albumin-to-creatinine ratio (UACR) as a routine recommendation. As Prof. Anderson emphasized, UACR is not only a marker of chronic kidney disease (CKD) but also, independent of estimated glomerular filtration rate (eGFR), a strong predictor of cardiovascular events, with important value for early identification of heart failure and overall cardiovascular risk.
Etiologic assessment is placed on par with hemodynamic management as a core priority. The practical session shared a highly representative case of an 81-year-old man with HFpEF. The patient presented with progressive exertional dyspnea, fatigue, and lower extremity edema. Echocardiography showed an LVEF of approximately 60% but with significant ventricular wall thickening, left atrial enlargement, and elevated left ventricular filling pressure. Careful history-taking provided crucial clues: a history of bilateral carpal tunnel release surgery, peripheral neuropathy, and a permanent pacemaker implanted two years earlier for complete atrioventricular block. These cross-system “red flags” strongly suggested underlying cardiac amyloidosis.
Following the guideline-recommended etiologic screening pathway, the patient underwent systematic diagnostic workup. Serum free light chain assay and serum/urine immunofixation electrophoresis were negative, ruling out AL amyloidosis (a plasma cell disorder requiring urgent treatment). Subsequent technetium-99m-labeled 3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) bone scintigraphy showed grade 3 diffuse myocardial uptake, and combined with clinical and imaging findings, the patient was ultimately diagnosed with wild-type transthyretin amyloid cardiomyopathy (wtATTR-CM). The complete diagnostic pathway in this case reflects the 2026 ESC guideline emphasis on “early identification and timely etiology-directed treatment.”
The diagnostic workflow for cardiac amyloidosis is also clearly defined in the guidelines: serum and urine immunofixation electrophoresis and serum free light chain quantification, combined with DPD/pyrophosphate (PYP)/hydroxymethylene diphosphonate (HMDP) bone scintigraphy, form the initial diagnostic “trio.” Note that monoclonal protein screening is not a single blood test; it requires simultaneous serum immunofixation electrophoresis, urine immunofixation electrophoresis, and serum free light chain quantification. If monoclonal screening is abnormal, ATTR-CM cannot be diagnosed even when DPD is positive, since data show that approximately one-third of AL amyloidosis patients may have positive DPD. After diagnosis of ATTR-CM, TTR silencers or stabilizers receive a class IA recommendation. Regardless of age, TTR genetic testing should be considered to distinguish wild-type from variant disease, which has important screening implications for family members.
Decompensated HF and Advanced HF: Renaming and Upgraded Recommendations
Another highlight of the new guidelines is the formal renaming of “acute heart failure” to “decompensated heart failure.” Heart failure symptoms and signs may develop acutely or gradually worsen, reaching a severity that requires urgent medical attention and initiation or intensification of treatment. This update more accurately reflects that cardiac function deterioration can occur acutely or progress gradually, and is not always a sudden event, while aligning with the most recent Universal Definition of Heart Failure.
For the inpatient management of decompensated HF, several new studies provide strong evidence for clinical decision-making. The PUSH-AHF study showed that urine sodium-guided diuretic therapy significantly increased 24-hour urine sodium excretion and urine output, while the ENACT-HF study demonstrated that a protocolized diuretic strategy effectively shortened hospital stay. Based on this evidence, the guidelines list urine sodium-guided diuretic therapy as a class IIb recommendation, and elevate intravenous acetazolamide or oral hydrochlorothiazide as second-line diuretics (added in patients already receiving loop diuretics with persistent fluid retention) to a class IIa recommendation. In addition, early in-hospital initiation of SGLT2 inhibitors after initial stabilization receives a class I recommendation (evidence level B1) for improving symptoms, quality of life, and reducing rehospitalization.
For cardiogenic shock, the DanGer Shock trial showed benefit with a microaxial flow pump in selected patients with STEMI-related cardiogenic shock, but a large meta-analysis showed no benefit in non-selected patients. The guidelines accordingly assign a class IIa recommendation for microaxial flow pumps in selected patients, while explicitly assigning a class III (contraindicated) recommendation in non-selected patients, emphasizing that device selection must be based on strict screening and multidisciplinary team evaluation.
Diagnostic criteria for advanced HF have also been loosened. The new guidelines adjust the diagnostic threshold: a patient with two unplanned HF hospitalizations, or even a single event requiring inotropic or vasoactive support for hypoperfusion, may meet the criteria for advanced HF. In addition, the guidelines assign a class I recommendation (evidence level A) emphasizing “early consultation” with advanced HF centers, and introduce the “Rule of Three” (involving HF hospitalization, diuretic resistance, and intolerance to foundational medical therapy with declining cardiopulmonary reserve) and the “I NEED HELP” criteria as practical referral triggers for identifying high-risk patients.
At the therapeutic level, the recommendation for left ventricular assist device (LVAD) is formally upgraded from class IIa to class I (evidence level C). This upgrade places LVAD on the same level of importance as heart transplantation for advanced HF treatment. The HELP-HF registry demonstrated that patients who do not receive LVAD or transplantation have extremely poor outcomes, while modern LVAD devices now provide significantly improved survival rates, allowing patients more time as they await transplantation or as destination therapy.
Conclusion
The significance of the 2026 ESC heart failure guidelines extends well beyond terminology changes. From removing HFmrEF to introducing the FMT concept, from age-stratified natriuretic peptide thresholds to early referral in advanced HF, every update conveys the same signal: heart failure management is moving from “LVEF-based broad classification”to “pathophysiology- and phenotype-based precision individualization.”
Of course, guideline implementation still faces challenges, including the resource burden of increased outpatient follow-up frequency, primary-care familiarity with new diagnostic workflows, and access disparities across health systems. But as Prof. Adamo noted, the guidelines provide an “evidence-based framework” rather than a “rigid template”; clinicians need to integrate individual patient context, local resources, and patient preferences to make the best decisions. As new drugs and devices continue to emerge, this dynamic system will continue to evolve.